Background: and Purpose Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. Methods: We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. Results: The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15–87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse.Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. Conclusions This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.

Background: and Purpose Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. Methods: We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. Results: The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15–87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse.Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. Conclusions This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.

Background: and Purpose Treatments for neuromyelitis optica spectrum disorder (NMOSD) such as eculizumab, ravulizumab, satralizumab, and inebilizumab have significantly advanced relapse prevention, but they remain expensive. Rituximab is an off-label yet popular alternative that offers a cost-effective solution, but its real-world efficacy needs better quantification for guiding the application of newer approved NMOSD treatments (ANTs). This study aimed to determine real-world rituximab failure rates to anticipate the demand for ANTs and aid in resource allocation. Methods: We conducted a nationwide retrospective study involving 605 aquaporin-4-antibody-positive NMOSD patients from 22 centers in South Korea that assessed the efficacy and safety of rituximab over a median follow-up of 47 months. Results: The 605 patients treated with rituximab included 525 (87%) who received continuous therapy throughout the follow-up period (median=47 months, interquartile range=15–87 months). During this period, 117 patients (19%) experienced at least 1 relapse. Notably, 68 of these patients (11% of the total cohort) experienced multiple relapses or at least 1 severe relapse.Additionally, 2% of the patients discontinued rituximab due to adverse events, which included severe infusion reactions, neutropenia, and infections. Conclusions This study has confirmed the efficacy of rituximab in treating NMOSD, as evidenced by an 87% continuation rate among patients over a 4-year follow-up period. Nevertheless, the occurrence of at least one relapse in 19% of the cohort, including 11% who experienced multiple or severe relapses, and a 2% discontinuation rate due to adverse events highlight the urgent need for alternative therapeutic options.

Purpose: The study was undertaken to investigate the electromyographic activities of the gluteus maximus (GM), hamstring (HAM), and multifidus (MF) in three different sling locations during bridge exercise in the supine position. Methods: Twenty healthy male subjects participated. An electromyography device was used to measure the muscle activities of the GM, HAM, and MF muscles. Subjects were asked to perform bridge exercises with three different sling locations as follows: 1) Bridge exercise with an ankle sling; BEAS, 2) Bridge exercise with a calf sling; BECS, and 3) Bridge exercise with a knee sling; BEKS in random order. The analysis was conducted using one-way repeated ANOVA and the Bonferroni post hoc. Significance was set at α= 0.01. Results: HAM muscle activity was significantly different in the three conditions (BEAS, BECS, BEKS) (adjusted p-value [padj]< 0.01), and HAM muscle activity was significantly smaller during BEKS than during BEAS or BECS (padj < 0.01). Muscle activity ratio (GM/HAM) during BEKS was significantly greater than muscle activity ratios during BEAS or BECS (padj < 0.01). Conclusion BEKS is recommended to inhibit HAM muscle activity and improve the GM/HAM muscle activity ratio.

Purpose: The study was undertaken to investigate the electromyographic activities of the gluteus maximus (GM), hamstring (HAM), and multifidus (MF) in three different sling locations during bridge exercise in the supine position. Methods: Twenty healthy male subjects participated. An electromyography device was used to measure the muscle activities of the GM, HAM, and MF muscles. Subjects were asked to perform bridge exercises with three different sling locations as follows: 1) Bridge exercise with an ankle sling; BEAS, 2) Bridge exercise with a calf sling; BECS, and 3) Bridge exercise with a knee sling; BEKS in random order. The analysis was conducted using one-way repeated ANOVA and the Bonferroni post hoc. Significance was set at α= 0.01. Results: HAM muscle activity was significantly different in the three conditions (BEAS, BECS, BEKS) (adjusted p-value [padj]< 0.01), and HAM muscle activity was significantly smaller during BEKS than during BEAS or BECS (padj < 0.01). Muscle activity ratio (GM/HAM) during BEKS was significantly greater than muscle activity ratios during BEAS or BECS (padj < 0.01). Conclusion BEKS is recommended to inhibit HAM muscle activity and improve the GM/HAM muscle activity ratio.

Purpose: The study was undertaken to investigate the electromyographic activities of the gluteus maximus (GM), hamstring (HAM), and multifidus (MF) in three different sling locations during bridge exercise in the supine position. Methods: Twenty healthy male subjects participated. An electromyography device was used to measure the muscle activities of the GM, HAM, and MF muscles. Subjects were asked to perform bridge exercises with three different sling locations as follows: 1) Bridge exercise with an ankle sling; BEAS, 2) Bridge exercise with a calf sling; BECS, and 3) Bridge exercise with a knee sling; BEKS in random order. The analysis was conducted using one-way repeated ANOVA and the Bonferroni post hoc. Significance was set at α= 0.01. Results: HAM muscle activity was significantly different in the three conditions (BEAS, BECS, BEKS) (adjusted p-value [padj]< 0.01), and HAM muscle activity was significantly smaller during BEKS than during BEAS or BECS (padj < 0.01). Muscle activity ratio (GM/HAM) during BEKS was significantly greater than muscle activity ratios during BEAS or BECS (padj < 0.01). Conclusion BEKS is recommended to inhibit HAM muscle activity and improve the GM/HAM muscle activity ratio.

Purpose: The study was undertaken to investigate the electromyographic activities of the gluteus maximus (GM), hamstring (HAM), and multifidus (MF) in three different sling locations during bridge exercise in the supine position. Methods: Twenty healthy male subjects participated. An electromyography device was used to measure the muscle activities of the GM, HAM, and MF muscles. Subjects were asked to perform bridge exercises with three different sling locations as follows: 1) Bridge exercise with an ankle sling; BEAS, 2) Bridge exercise with a calf sling; BECS, and 3) Bridge exercise with a knee sling; BEKS in random order. The analysis was conducted using one-way repeated ANOVA and the Bonferroni post hoc. Significance was set at α= 0.01. Results: HAM muscle activity was significantly different in the three conditions (BEAS, BECS, BEKS) (adjusted p-value [padj]< 0.01), and HAM muscle activity was significantly smaller during BEKS than during BEAS or BECS (padj < 0.01). Muscle activity ratio (GM/HAM) during BEKS was significantly greater than muscle activity ratios during BEAS or BECS (padj < 0.01). Conclusion BEKS is recommended to inhibit HAM muscle activity and improve the GM/HAM muscle activity ratio.

Viral load and the duration of viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are important determinants of the transmission of coronavirus disease 2019.In this study, we examined the effects of viral doses on the lung and spleen of K18-hACE2 transgenic mice by temporal histological and transcriptional analyses. Approximately, 1×105 plaque-forming units (PFU) of SARS-CoV-2 induced strong host responses in the lungs from 2 days post inoculation (dpi) which did not recover until the mice died, whereas responses to the virus were obvious at 5 days, recovering to the basal state by 14 dpi at 1×102 PFU. Further, flow cytometry showed that number of CD8+ T cells continuously increased in 1×102 PFU-virusinfected lungs from 2 dpi, but not in 1×105 PFU-virus-infected lungs. In spleens, responses to the virus were prominent from 2 dpi, and number of B cells was significantly decreased at 1×105PFU; however, 1×102 PFU of virus induced very weak responses from 2 dpi which recovered by 10 dpi. Although the defense responses returned to normal and the mice survived, lung histology showed evidence of fibrosis, suggesting sequelae of SARS-CoV-2 infection. Our findings indicate that specific effectors of the immune response in the lung and spleen were either increased or depleted in response to doses of SARS-CoV-2. This study demonstrated that the response of local and systemic immune effectors to a viral infection varies with viral dose, which either exacerbates the severity of the infection or accelerates its elimination.

Background: A healthcare system’s collapse due to a pandemic, such as the coronavirus disease 2019 (COVID-19), can expose healthcare workers (HCWs) to various mental health problems. This study aimed to investigate the impact of the COVID-19 pandemic on the depression and anxiety of HCWs. Methods: A nationwide questionnaire-based survey was conducted on HCWs who worked in healthcare facilities and public health centers in Korea in December 2020. Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) were used to measure depression and anxiety. To investigate factors associated with depression and anxiety, stepwise multiple logistic regression analysis was performed. Results: A total of 1,425 participating HCWs were included. The mean depression score (PHQ-9) of HCWs before and after COVID-19 increased from 2.37 to 5.39, and the mean anxiety score (GAD-7) increased from 1.41 to 3.41. The proportion of HCWs with moderate to severe depression (PHQ-9 ≥ 10) increased from 3.8% before COVID-19 to 19.5% after COVID-19, whereas that of HCWs with moderate to severe anxiety (GAD-7 ≥ 10) increased from 2.0% to 10.1%. In our study, insomnia, chronic fatigue symptoms and physical symptoms after COVID-19, anxiety score (GAD-7) after COVID-19, living alone, and exhaustion were positively correlated with depression. Furthermore, post-traumatic stress symptoms, stress score (Global Assessment of Recent Stress), depression score (PHQ-9) after COVID-19, and exhaustion were positively correlated with anxiety. Conclusion In Korea, during the COVID-19 pandemic, HCWs commonly suffered from mental health problems, including depression and anxiety. Regularly checking the physical and mental health problems of HCWs during the COVID-19 pandemic is crucial, and social support and strategy are needed to reduce the heavy workload and psychological distress of HCWs.

Background/Aims: The prognostic significance of 18F-fluorodeoxyglucose (FDG)-positron emission tomography-computed tomography (PET/CT) in peripheral T-cell lymphomas (PTCLs) are controversial. We explored the prognostic impact of sequential 18F-FDG PET/CT during frontline chemotherapy of patients with PTCLs. Methods: In total, 143 patients with newly diagnosed PTCLs were included. Sequential 18F-FDG PET/CTs were performed at the time of diagnosis, during chemotherapy, and at the end of chemotherapy. The baseline total metabolic tumor volume (TMTV) was calculated using the the standard uptake value with a threshold method of 2.5. Results: A baseline TMTV of 457.0 cm3 was used to categorize patients into high and low TMTV groups. Patients with a requirehigh TMTV had shorter progression-free survival (PFS) and overall survival (OS) than those with a low TMTV (PFS, 9.8 vs. 26.5 mo, p = 0.043; OS, 18.9 vs. 71.2 mo, p = 0.004). The interim 18F-FDG PET/CT response score was recorded as 1, 2–3, and 4–5 according to the Deauville criteria. The PFS and OS showed significant differences according to the interim 18F-FDG PET/CT response score (PFS, 120.7 vs. 34.1 vs. 5.1 mo, p < 0.001; OS, not reached vs. 61.1 mo vs. 12.1 mo, p < 0.001). Conclusions The interim PET/CT response based on visual assessment predicts disease progression and survival outcome in PTCLs. A high baseline TMTV is associated with a poor response to anthracycline-based chemotherapy in PTCLs. However, TMTV was not an independent predictor for PFS in the multivariate analysis.